High-NA EUV Optimism Clashes with ASML's Elevated Risks and Rich Valuation

What happened

A recent article highlights ASML's High-NA EUV technology moving into early adoption, potentially accelerating long-term revenue growth on AI-driven chip demand and advanced node transitions. However, the DeepValue master report maintains a 'WAIT' rating, noting the stock's 46.8x P/E and 35.5x EV/EBITDA already discount a smooth AI-driven ramp with thin margin of safety. ASML exited FY2025 with a robust €38.8B backlog and Q4’25 net bookings of €13.2B, supporting FY2026 sales guidance of €34B–€39B. Critical risks include export controls, China revenue normalization from 29.1% in 2025 toward ~20% in 2026, and sole-supplier dependency on Carl Zeiss SMT for optics. Thus, while High-NA adoption aligns with the bull scenario, investors must await Q1-Q2’26 execution to confirm bookings conversion and mitigate policy or supply-chain shocks.

Implication

The article's focus on High-NA EUV as a growth accelerator reinforces ASML's technological moat but does not address near-term execution risks flagged in filings, such as export-control impacts or raw-material shortages. With the stock priced at 46.8x P/E, any deviation from the €34B–€39B sales guide or China mix step-down could trigger significant downside, as the market has crowdedly priced in AI-driven optimism. AI demand supports backlog, but China's revenue decline and potential service impairments require careful monitoring to avoid revenue deferrals. Supply-chain fragility, particularly the single-source optics from Carl Zeiss, remains an existential threat that could disrupt shipments and erode cash flow despite strong free cash flow of ~$10.6B. Therefore, a cautious stance is warranted until Q1-Q2’26 results validate guidance sustainability and risk management, aligning with the report's 'WAIT' rating and €1250 attractive entry point.

Thesis delta

The article underscores High-NA EUV's role in ASML's long-term growth, aligning with the bull scenario's emphasis on technology monetization, but it introduces no new data to alter the core investment thesis. The thesis remains unchanged: ASML's success hinges on converting its €38.8B backlog amid AI tailwinds while navigating export controls, China normalization, and supply-chain constraints, with valuation demanding proof from quarterly execution before any rating upgrade.